Cover Image

Pharmacogenetic guided drug therapy: how to deal with phenoconversion in polypharmacy

The prevalence of polypharmacy and the increasing availability of pharmacogenetic information in clinical practice have raised the prospect of data-driven clinical decision-making when addressing the issues of drug-drug interactions and genetic polymorphisms in metabolizing enzymes. Inhibition of me...

Full description

Saved in:
Bibliographic Details
Main Authors: Stingl, Julia (Author) , Viviani, Roberto (Author)
Format: Article (Journal)
Language:English
Published: 16 January 2025
In: Expert opinion on drug metabolism & toxicology
Year: 2025, Volume: 21, Issue: 4, Pages: 399-407
ISSN:1744-7607
DOI:10.1080/17425255.2025.2451440
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1080/17425255.2025.2451440
Verlag, kostenfrei, Volltext: https://www.tandfonline.com/doi/full/10.1080/17425255.2025.2451440
Get full text
Author Notes:Julia Carolin Stingl and Roberto Viviani

MARC

LEADER 00000naa a2200000 c 4500
001 193223411X
003 DE-627
005 20250731172403.0
007 cr uuu---uuuuu
008 250731s2025 xx |||||o 00| ||eng c
024 7 |a 10.1080/17425255.2025.2451440  |2 doi 
035 |a (DE-627)193223411X 
035 |a (DE-599)KXP193223411X 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Stingl, Julia  |d 1971-  |e VerfasserIn  |0 (DE-588)118131451  |0 (DE-627)694697990  |0 (DE-576)291731384  |4 aut 
245 1 0 |a Pharmacogenetic guided drug therapy  |b how to deal with phenoconversion in polypharmacy  |c Julia Carolin Stingl and Roberto Viviani 
264 1 |c 16 January 2025 
300 |b Illustrationen 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 31.07.2025 
520 |a The prevalence of polypharmacy and the increasing availability of pharmacogenetic information in clinical practice have raised the prospect of data-driven clinical decision-making when addressing the issues of drug-drug interactions and genetic polymorphisms in metabolizing enzymes. Inhibition of metabolizing enzymes in drug interactions can lead to genotype-phenotype discrepancies (phenoconversion) that reduce the relevance of individual pharmacogenetic information. The aim of this review is to provide an overview of existing models of phenoconversion, and we discuss how phenoconversion models may be developed to estimate joint drug-interactions and genetic effects. Based on a literature search in PubMed, Google Scholar, and reference lists from review articles, we provide an overview of the current models of phenoconversion. The currently applied phenoconversion models are presented and discussed to predict the effects of drug-drug interactions while accounting for the pharmacogenetic status of patients. While pharmacogenetic-dose recommendations alone are most relevant for rare and extreme genotypes, phenoconversion may increase the prevalence of these phenotypes. Therefore, in polypharmacy conditions, phenoconversion assessment is especially important for personalized drug therapy. 
650 4 |a drug-drug-gene interaction 
650 4 |a Pharmacogenetics 
650 4 |a phenoconversion 
650 4 |a phenotypic models 
650 4 |a polypharmacy 
700 1 |a Viviani, Roberto  |e VerfasserIn  |0 (DE-588)1372861963  |0 (DE-627)1932234373  |4 aut 
773 0 8 |i Enthalten in  |t Expert opinion on drug metabolism & toxicology  |d Abingdon, Oxon : Routledge, Taylor & Francis, 2005  |g 21(2025), 4, Seite 399-407  |h Online-Ressource  |w (DE-627)588196576  |w (DE-600)2470760-0  |w (DE-576)302970746  |x 1744-7607  |7 nnas  |a Pharmacogenetic guided drug therapy how to deal with phenoconversion in polypharmacy 
773 1 8 |g volume:21  |g year:2025  |g number:4  |g pages:399-407  |g extent:9  |a Pharmacogenetic guided drug therapy how to deal with phenoconversion in polypharmacy 
856 4 0 |u https://doi.org/10.1080/17425255.2025.2451440  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.tandfonline.com/doi/full/10.1080/17425255.2025.2451440  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250731 
993 |a Article 
994 |a 2025 
998 |g 118131451  |a Stingl, Julia  |m 118131451:Stingl, Julia  |d 910000  |d 910100  |e 910000PS118131451  |e 910100PS118131451  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN193223411X  |e 4751634356 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"role":"aut","given":"Julia","family":"Stingl","display":"Stingl, Julia"},{"display":"Viviani, Roberto","family":"Viviani","role":"aut","given":"Roberto"}],"language":["eng"],"note":["Gesehen am 31.07.2025"],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"16 January 2025"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Pharmacogenetic guided drug therapy","subtitle":"how to deal with phenoconversion in polypharmacy","title_sort":"Pharmacogenetic guided drug therapy"}],"recId":"193223411X","name":{"displayForm":["Julia Carolin Stingl and Roberto Viviani"]},"physDesc":[{"extent":"9 S.","noteIll":"Illustrationen"}],"relHost":[{"language":["eng"],"part":{"issue":"4","extent":"9","volume":"21","year":"2025","text":"21(2025), 4, Seite 399-407","pages":"399-407"},"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 03.09.15"],"origin":[{"publisher":"Routledge, Taylor & Francis ; Informa Healthcare","dateIssuedKey":"2005","dateIssuedDisp":"2005-","publisherPlace":"Abingdon, Oxon ; London [u.a.]"}],"title":[{"title_sort":"Expert opinion on drug metabolism & toxicology","title":"Expert opinion on drug metabolism & toxicology"}],"disp":"Pharmacogenetic guided drug therapy how to deal with phenoconversion in polypharmacyExpert opinion on drug metabolism & toxicology","id":{"eki":["588196576"],"issn":["1744-7607"],"zdb":["2470760-0"]},"recId":"588196576","pubHistory":["1.2005 -"],"physDesc":[{"extent":"Online-Ressource"}]}],"id":{"doi":["10.1080/17425255.2025.2451440"],"eki":["193223411X"]}} 
SRT |a STINGLJULIPHARMACOGE1620 

Similar Items